A phase 2 clinical trial of the pharmacological chaperone AT2101 for the treatment of Gaucher disease

被引：0
|
作者：
Weinreb, N. [1 ]
Schneider, E. [2 ]
Dinh, Q. [2 ]
Duke, C. [2 ]
Insinga, A. F. [2 ]
Scott, K. [2 ]
Do, H. [2 ]
Wustman, B. [2 ]
Palling, D. [2 ]
Lockhart, D. J. [2 ]
机构：
[1] Res Fdn LSDs Inc, Coral Springs, FL USA
[2] Amicus Therapeut Inc, Cranbury, NJ USA
来源：
JOURNAL OF INHERITED METABOLIC DISEASE | 2008年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
427P
引用
收藏
页码：108 / 108
页数：1
相关论文
共 50 条
  • [41] Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat
    Ravi S. Kamath
    Elena Lukina
    Nora Watman
    Marta Dragosky
    Gregory M. Pastores
    Elsa Avila Arreguin
    Hanna Rosenbaum
    Ari Zimran
    Rasha Aguzzi
    Ana Cristina Puga
    Andrea M. Norfleet
    M. Judith Peterschmitt
    Daniel I. Rosenthal
    Skeletal Radiology, 2014, 43 : 1353 - 1360
  • [42] Commentary on "Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease" by Zimran et al.
    Goker-Alpan, Ozlem
    BLOOD CELLS MOLECULES AND DISEASES, 2013, 50 (02) : 138 - 139
  • [43] Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies
    Dominique P Germain
    Roberto Giugliani
    Derralynn A Hughes
    Atul Mehta
    Kathy Nicholls
    Laura Barisoni
    Charles J Jennette
    Alexander Bragat
    Jeff Castelli
    Sheela Sitaraman
    David J Lockhart
    Pol F Boudes
    Orphanet Journal of Rare Diseases, 7
  • [44] Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies
    Germain, Dominique P.
    Giugliani, Roberto
    Hughes, Derralynn A.
    Mehta, Atul
    Nicholls, Kathy
    Barisoni, Laura
    Jennette, Charles J.
    Bragat, Alexander
    Castelli, Jeff
    Sitaraman, Sheela
    Lockhart, David J.
    Boudes, Pol F.
    ORPHANET JOURNAL OF RARE DISEASES, 2012, 7
  • [45] Preliminary results of a phase II clinical trial of Genz-112638 in patients with type I Gaucher disease
    Peterschmitt, Judith
    Lukina, Elena
    Watman, Nora
    Banikazemi, Maryam
    Iastrebner, Marcelo
    Rosenbaum, Hanna
    Zimran, Ari
    Arreguin, Elsa Avila
    O'Brien, Fanny
    Smith, Sharon
    Puga, Ana Cristina
    MOLECULAR GENETICS AND METABOLISM, 2008, 93 (02) : S32 - S33
  • [46] Pharmacological Dependency in Chronic Treatment of Gastroesophageal Reflux Disease: A Randomized Controlled Clinical Trial
    van der Velden, A. W.
    de Wit, N. J.
    Quartero, A. O.
    Grobbee, D. E.
    Numans, M. E.
    DIGESTION, 2010, 81 (01) : 43 - 52
  • [47] PRELIMINARY RESULTS OF A PHASE II CLINICAL TRIAL OF GENZ-112638 IN PATIENTS WITH TYPE 1 GAUCHER DISEASE
    Puga, A. Cristina
    Lukina, E.
    Watman, N.
    Banikazemi, M.
    Iastrebner, M.
    Rosenbaum, H.
    Zimran, A.
    Arreguin, E. Avila
    O'Brien, F.
    Smith, S. E.
    Peterschmitt, J.
    CLINICAL THERAPEUTICS, 2008, 30 : S103 - S104
  • [48] GAUCHER DISEASE - CLINICAL ASPECTS, MOLECULAR-BIOLOGY AND TREATMENT
    BEUTLER, E
    AMERICAN JOURNAL OF HUMAN GENETICS, 1991, 49 (04) : 58 - 58
  • [49] Design and synthesis of highly potent and selective pharmacological chaperones for the treatment of Gaucher's disease
    Compain, Philippe
    Martin, Olivier R.
    Boucheron, Charlotte
    Godin, Guillaume
    Yu, Liang
    Ikeda, Kyoko
    Asano, Naoki
    CHEMBIOCHEM, 2006, 7 (09) : 1356 - 1359
  • [50] Second-Generation Iminoxylitol-Based Pharmacological Chaperones for the Treatment of Gaucher Disease
    Oulaidi, Farah
    Front-Deschamps, Sophie
    Gallienne, Estelle
    Lesellier, Eric
    Ikeda, Kyoko
    Asano, Naoki
    Compain, Philippe
    Martin, Olivier R.
    CHEMMEDCHEM, 2011, 6 (02) : 353 - 361
12345